BioTime News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.01.25	Lineage Cell Therapeutics Issues Letter to Stockholders (Businesswire)
21.11.24	Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering (Businesswire)
20.11.24	Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering (Businesswire)
14.11.24	Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (Businesswire)
13.11.24	Ausblick: BioTime präsentiert Quartalsergebnisse (finanzen.net)
07.11.24	Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 (Businesswire)
14.10.24	Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit (Businesswire)
25.09.24	OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium (Businesswire)
18.09.24	Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop (Businesswire)
13.08.24	Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (Businesswire)
08.08.24	Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (Businesswire)
07.08.24	Ausblick: BioTime präsentiert Quartalsergebnisse (finanzen.net)
01.08.24	Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Businesswire)
02.07.24	Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index (Businesswire)
30.05.24	Lineage to Present at 2024 BIO International Convention (Businesswire)
21.05.24	Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium (Businesswire)
09.05.24	Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (Businesswire)
08.05.24	Ausblick: BioTime legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
06.05.24	OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit (Businesswire)
02.05.24	Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (Businesswire)
30.04.24	Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Businesswire)
29.04.24	Lineage Announces Changes to Board of Directors (Businesswire)
01.04.24	Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development (Businesswire)
18.03.24	Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium (Businesswire)
13.03.24	RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit (Businesswire)
11.03.24	RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting (Businesswire)
07.03.24	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (Businesswire)
06.03.24	Ausblick: BioTime legt Zahlen zum jüngsten Quartal vor (finanzen.net)
29.02.24	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 (Businesswire)
13.02.24	Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury (Businesswire)
09.02.24	Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering (Businesswire)
06.02.24	Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering (Businesswire)
16.01.24	RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS (Businesswire)
18.12.23	Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury (Businesswire)
09.11.23	Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (Businesswire)
08.11.23	Ausblick: BioTime stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
01.11.23	Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023 (Businesswire)
24.10.23	RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting (Businesswire)
11.10.23	Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells (Businesswire)
05.10.23	RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Businesswire)
19.09.23	Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023 (Businesswire)
13.09.23	RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress (Businesswire)
11.09.23	Lineage to Present at 2023 International Spinal Research Trust Network Meeting (Businesswire)
06.09.23	Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics (Businesswire)
29.08.23	Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference (Businesswire)
10.08.23	Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (Businesswire)
09.08.23	Ausblick: BioTime gewährt Anlegern Blick in die Bücher (finanzen.net)
03.08.23	Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (Businesswire)
24.07.23	Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer (Businesswire)
22.05.23	Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’304.50	2.84 %	K V
Holcim	89.42	1.52 %	K V
ABB	49.94	0.93 %	K V
Roche Hldg G	266.10	0.64 %	K V
Nestle	75.40	0.61 %	K V
Kuehne+Nagel Int	207.70	-0.38 %	K V
CieFinRichemont	140.15	-0.43 %	K V
Zurich Insur Gr	549.40	-0.43 %	K V
Givaudan	3’883.00	-0.51 %	K V
Logitech Intl	78.86	-1.28 %	K V

Nachrichten zu BioTime Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten